KPV
KPV is a naturally occurring tripeptide derived from alpha-melanocyte-stimulating hormone (α-MSH). In cell-culture studies and mouse colitis models it has shown anti-inflammatory activity relevant to intestinal inflammation.
Regulatory status (as of Sept 2026)
Not FDA-approved. Removed from 503A Category 2 on April 15, 2026. PCAC recommended for the 503A Bulks List (advisory); awaiting FDA rulemaking; not lawfully compoundable under 503A as of Sept 17, 2026. PCAC vote: 8–6–1 (yes–no–abstain), July 23, 2026.
See the FDA peptide regulatory tracker · Read our July 27, 2026 dispatch on the FDA PCAC peptide vote5 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content
KPV is a compound studied only in animals and lab experiments so far. KPV is a naturally occurring tripeptide derived from alpha-melanocyte-stimulating hormone (α-MSH).
| Half-life | Not established in published research |
|---|---|
| How it's given in studies | Subcutaneous injection, Oral, Topical |
| Research stage | Preclinical (animal) |
| Dosing | Published research: No published human dosing detailsNanomolar concentrations in human intestinal epithelial and T-cell culture; KPV added to drinking water (oral) in DSS- and TNBS-induced colitis in mice; KPV-loaded hyaluronic-acid nanoparticles delivered orally in a mouse ulcerative colitis model.Community-reportedCommunity-reported: 200–500 mcg, subcutaneous injection, Oral, Topical |
Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.
Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies
In plain terms: It is a tiny peptide that calmed inflammation signals in lab cells and in mice with gut inflammation. Proposed mechanism, from human cell cultures and mouse colitis models (Dalmasso 2008): KPV is taken up into intestinal epithelial and immune cells by the PepT1 transporter and, at nanomolar concentrations, inhibited NF-κB and MAP-kinase inflammatory signalling and reduced pro-inflammatory cytokine secretion. As a fragment of α-MSH, it is described as retaining anti-inflammatory activity without melanocortin-mediated pigmentation effects.
How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.
Community-reportedIn user communities, KPV is typically run at 200–500 mcg (subcutaneous injection, oral, topical). This is not a recommendation.
Side effects reported in studies are listed separately below.
Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.
KPV is a C-terminal tripeptide fragment (amino acids 11-13) of alpha-melanocyte-stimulating hormone (α-MSH), consisting of the amino acids lysine-proline-valine. Despite its small size, KPV retains the full anti-inflammatory activity of the parent hormone while lacking its pigmentation effects. In cultured human intestinal epithelial and T cells, KPV inhibited NF-κB and MAP-kinase signalling at nanomolar concentrations. KPV works primarily by entering cells and inhibiting the NF-κB signaling cascade, which is a master regulator of inflammation. In mice, oral KPV reduced the incidence and severity of chemically induced (DSS and TNBS) colitis; the published evidence found is limited to cell culture and mouse models. The peptide's small size, stability, and multiple routes of administration (injectable, oral, and topical) make it a versatile research compound.
Lys-Pro-Val (3 amino acids)
Molecular Weight: 342.4 Da
Molecular Formula: C16H30N4O4
Structure Details: Linear tripeptide consisting of lysine, proline, and valine. C-terminal fragment (residues 11-13) of α-MSH. The compact structure contributes to stability and cellular penetration.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
| Peptide | Half-Life | Route | Research Status |
|---|---|---|---|
| KPV | No published PK data found | Subcutaneous injection, Oral, Topical | Preclinical (animal) |
| LL-37 | Unknown | Subcutaneous injection | Phase 2 |
| Thymalin | No published PK data found | Intramuscular injection | Approved outside US |
| Thymopoietin II Fragment (TP-1) | Unknown | Subcutaneous injection | Preclinical (animal) |
| Thymosin Alpha-1 | No published human PK data found; ~3 h for native Tα1 in rats (Shen 2019). Literature describes a 'short plasma half-life' requiring twice-weekly s.c. dosing. | Subcutaneous injection | Approved outside US |
Values reflect figures reported in published research. Compare any peptides side-by-side →
This peptide belongs to the Immune category. View All Immune Peptides
Healing, Anti-Aging
From Our Affiliated Clinic
1836 Wellness is a physician-supervised clinic in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
See how it works →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.